Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J2MJ
|
|||
| Drug Name |
Selegiline Hydrochloride
|
|||
| Synonyms |
Selegiline hydrochloride; 14611-52-0; Selegiline Hcl; (-)-Deprenyl hydrochloride; l-Deprenyl hydrochloride; Jumex hydrochloride; Eldepryl hydrochloride; (-)-Deprenil hydrochloride; (R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride; (-)-E-250 hydrochloride; UNII-6W731X367Q; HSDB 7183; R-(-)-Deprenyl (hydrochloride); FPF1100; (-)-Phenylisopropylmethylpropynylamine; 6W731X367Q; (-)-(R)-N,alpha-Dimethyl-N-2-propynylphenethylamine hydrochloride; Zydis selegiline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Approved | [1] | |
| Motor symptoms [ICD-11: 6A25.4] | Investigative | [2] | ||
| Therapeutic Class |
Neurology Agents
|
|||
| Company |
Somerset Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H18ClN
|
|||
| Canonical SMILES |
CC(CC1=CC=CC=C1)N(C)CC#C.Cl
|
|||
| InChI |
1S/C13H17N.ClH/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13;/h1,5-9,12H,10-11H2,2-3H3;1H/t12-;/m1./s1
|
|||
| InChIKey |
IYETZZCWLLUHIJ-UTONKHPSSA-N
|
|||
| CAS Number |
CAS 14611-52-0
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:9087
|
|||
| ADReCS Drug ID | BADD_D02003 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Monoamine oxidase type B (MAO-B) | Target Info | Modulator | [2], [3] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation via tryptamine | ||||
| Dopamine degradation | ||||
| Putrescine degradation III | ||||
| Noradrenaline and adrenaline degradation | ||||
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| Histidine metabolism | ||||
| Tyrosine metabolism | ||||
| Phenylalanine metabolism | ||||
| Tryptophan metabolism | ||||
| Drug metabolism - cytochrome P450 | ||||
| Metabolic pathways | ||||
| Serotonergic synapse | ||||
| Dopaminergic synapse | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| 5-Hydroxytryptamine degredation | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| WikiPathways | Tryptophan metabolism | |||
| Dopamine metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.